RudaCure CEO Yongho Kim and BD team member Harris Hasrol participó in the University of Utah tecnología briefing held from September 25 to 29, where they promovió la empresa's technologies to U.S.-based venture capitalists and realizó inversión meetings.
Según their report, there was strong interest from local attendees in the tratamiento del dolor crónico, as well as significant attention toward the tratamiento de la enfermedad de ojo seco and daño corneal recovery agent currently in clinical preparation. The reception indicated an active desire to move forward with investigación conjunta and inversión opportunities.
It is esperado that the investor presentación taking place in San Francisco from October 2nd onward will also yield positive resultados.
Following the San Francisco investor presentación, BD team member Harris Hasrol will travel to Singapore to attend the Shinhan Square Bridge-organized investor roadshow (October 10–13), where he will present la empresa's technologies to Asian inversores. He will then travel to Europe to attend Bio Europe, where he planea discuss specific details of transferencia de tecnología with Ceva, with whom RudaCure actualmente está in discussions regarding veterinario desarrollo de fármacos.